Agree with your incisive comment. My estimate is that there is sufficient time to develop a clearly focused target for ECOR VNS therapy that is important clinically in an acute care setting (not a Class II home care device) and to build a business plan around that project. That plan, supported by existing ECOR data and some additional data, may be sufficient to raise additional capital and to salvage ECOR as an independent company or to set the stage for an M&A event.
This strategy would mean acknowledging that ECOR as currently positioned has failed as a commercial venture. A good part of G&A would need to be reduced or eliminated, especially that staff without experience with MedTech in acute care settings. I don't know the CEO, but suspect that this project would not be his cup of tea. ECOR needs a more relevant Board as well.
News 
Market Data 
Discover 
